Module

New Findings on Resistance to NRTIs, NNRTIs, and PIs

Source: HIV/AIDS Annual Update 2008

New Findings on Resistance to NRTIs, NNRTIs, and PIs

Faculty:
Daniel R. Kuritzkes, MD

CME CREDIT INFORMATION

Release Date: 06/02/08

Expiration Date: 06/01/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.0 contact hour (0.1 CEUs)

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the clinical impact of HIV-1 drug resistance
Review the prevalence of HIV-1 drug resistant mutations, as well as currently available detection assays
Describe identified mutations that confer resistance to novel antiretroviral agents

Topics covered include:

Introduction
The Changing Epidemiology and Clinical Consequences of Drug Resistance
Clinical Significance of Transmitted Drug Resistance
Clinical Significance of Minor Variants
NRTI Resistance: The RNase H Connection
NNRTI Resistance: Predictors of Etravirine Activity
PI Resistance
Conclusions
Summary—Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.